Crespo Maria J, Quidgley José A
Department of Physiology, University of Puerto Rico School of Medicine, San Juan, Puerto Rico.
Pharmacology. 2006;76(3):141-7. doi: 10.1159/000091045. Epub 2006 Jan 20.
Recent evidence suggests that statins improve the status of patients with coronary artery disease not only by reducing cholesterol levels, but also by acting at the level of the endothelium-smooth muscle unit. Previous results from our laboratory showed that these drugs interact with the vascular wall by partially inhibiting calcium-dependent, agonist-induced contractions in rat aortas. To evaluate whether this effect is also extended to the coronary vasculature, we assessed the effect of statins on serotonin (5-HT) induced contractions of left and right coronary arteries of swine. Concentration-response curves for the 5-HT-induced contractions (from 0.1 nmol/l to 100 micromol/l) were calculated on rings from both coronaries in the presence and absence of either (5 micromol/l) pravastatin, mevastatin, simvastatin, lovastatin, or atorvastatin. After a 45-min incubation period, all statins significantly reduced the Emax for the 5-HT-induced contractions, ranging from 51.9 +/- 1.9% (simvastatin) to 15.9 +/- 2.0% (pravastatin) in the left coronary artery and from 48.8 +/- 2.0% (simvastatin) to 17.8 +/- 2.5% (pravastatin) in the right coronary artery. The EC50 values for the 5-HT-induced contractions were 0.150 +/- 0.005 micromol/l for the left coronary artery and 0.171 +/- 0.010 micromol/l for the right coronary artery. These values significantly changed after incubation with statins, ranging from 1.240 +/- 0.101 micromol/l (for simvastatin) to 0.081+/- 0.008 micromol/l (for pravastatin) in the left coronary artery and from 1.410 +/- 0.075 micromol/l (for simvastatin) to 0.084 +/- 0.008 micromol/l (for pravastatin) in the right coronary artery. This evidence supports the possibility that, beyond their lipid-lowering properties, statins may provide a beneficial effect in atherosclerotic patients by reducing the tone in the coronary vasculature, facilitating blood flow to the myocardium.
近期证据表明,他汀类药物改善冠状动脉疾病患者的状况,不仅是通过降低胆固醇水平,还通过作用于内皮-平滑肌单元水平。我们实验室之前的结果显示,这些药物通过部分抑制大鼠主动脉中钙依赖性、激动剂诱导的收缩,与血管壁相互作用。为了评估这种效应是否也扩展到冠状动脉系统,我们评估了他汀类药物对猪左、右冠状动脉中5-羟色胺(5-HT)诱导收缩的影响。在存在或不存在(5微摩尔/升)普伐他汀、美伐他汀、辛伐他汀、洛伐他汀或阿托伐他汀的情况下,计算了来自两根冠状动脉环的5-HT诱导收缩(从0.1纳摩尔/升到100微摩尔/升)的浓度-反应曲线。在45分钟的孵育期后,所有他汀类药物均显著降低了5-HT诱导收缩的最大效应(Emax),在左冠状动脉中从51.9±1.9%(辛伐他汀)到15.9±2.0%(普伐他汀),在右冠状动脉中从48.8±2.0%(辛伐他汀)到17.8±2.5%(普伐他汀)。5-HT诱导收缩的半数有效浓度(EC50)值,左冠状动脉为0.150±0.005微摩尔/升,右冠状动脉为0.171±0.010微摩尔/升。与他汀类药物孵育后,这些值发生了显著变化,在左冠状动脉中从1.240±0.101微摩尔/升(辛伐他汀)到0.081±0.008微摩尔/升(普伐他汀),在右冠状动脉中从1.410±0.075微摩尔/升(辛伐他汀)到0.084±0.008微摩尔/升(普伐他汀)。这一证据支持了这样一种可能性,即除了其降脂特性外,他汀类药物可能通过降低冠状动脉系统的张力,促进心肌血流,为动脉粥样硬化患者带来有益影响。